vs
Side-by-side financial comparison of Kennedy-Wilson Holdings, Inc. (KW) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $120.6M, roughly 1.3× Kennedy-Wilson Holdings, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 48.1%, a 23.1% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -11.0%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $-55.2M).
Kennedy Wilson is a real estate investment company headquartered in Beverly Hills, California, United States.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
KW vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $120.6M | $158.6M |
| Net Profit | $58.0M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 57.3% | 70.2% |
| Net Margin | 48.1% | 71.2% |
| Revenue YoY | -11.0% | 3661.1% |
| Net Profit YoY | 32.7% | 528.0% |
| EPS (diluted) | $0.22 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.6M | — | ||
| Q3 25 | $116.4M | — | ||
| Q2 25 | $135.7M | — | ||
| Q1 25 | $128.3M | $158.6M | ||
| Q4 24 | $135.5M | $22.6M | ||
| Q3 24 | $127.5M | — | ||
| Q2 24 | $132.0M | — | ||
| Q1 24 | $136.4M | — |
| Q4 25 | $58.0M | — | ||
| Q3 25 | $-10.2M | — | ||
| Q2 25 | $5.6M | — | ||
| Q1 25 | $-29.6M | $112.9M | ||
| Q4 24 | $43.7M | $-10.5M | ||
| Q3 24 | $-66.8M | — | ||
| Q2 24 | $-48.3M | — | ||
| Q1 24 | $37.7M | — |
| Q4 25 | 57.3% | — | ||
| Q3 25 | -6.2% | — | ||
| Q2 25 | 7.4% | — | ||
| Q1 25 | -26.9% | 70.2% | ||
| Q4 24 | 36.7% | -60.4% | ||
| Q3 24 | -60.8% | — | ||
| Q2 24 | -45.5% | — | ||
| Q1 24 | 47.2% | — |
| Q4 25 | 48.1% | — | ||
| Q3 25 | -8.8% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | -23.1% | 71.2% | ||
| Q4 24 | 32.3% | -46.4% | ||
| Q3 24 | -52.4% | — | ||
| Q2 24 | -36.6% | — | ||
| Q1 24 | 27.6% | — |
| Q4 25 | $0.22 | — | ||
| Q3 25 | $-0.15 | — | ||
| Q2 25 | $-0.05 | — | ||
| Q1 25 | $-0.30 | $1.90 | ||
| Q4 24 | $0.24 | $-0.15 | ||
| Q3 24 | $-0.56 | — | ||
| Q2 24 | $-0.43 | — | ||
| Q1 24 | $0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $184.5M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.5B | $350.1M |
| Total Assets | $6.6B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $184.5M | — | ||
| Q3 25 | $382.6M | — | ||
| Q2 25 | $309.1M | — | ||
| Q1 25 | $356.6M | $274.8M | ||
| Q4 24 | $217.5M | $128.0M | ||
| Q3 24 | $367.1M | — | ||
| Q2 24 | $366.5M | — | ||
| Q1 24 | $541.9M | — |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.6B | $350.1M | ||
| Q4 24 | $1.6B | $229.0M | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.7B | — |
| Q4 25 | $6.6B | — | ||
| Q3 25 | $6.7B | — | ||
| Q2 25 | $6.8B | — | ||
| Q1 25 | $7.2B | $406.9M | ||
| Q4 24 | $7.0B | $271.6M | ||
| Q3 24 | $7.4B | — | ||
| Q2 24 | $7.5B | — | ||
| Q1 24 | $7.7B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.4M | $131.8M |
| Free Cash FlowOCF − Capex | $-55.2M | $131.7M |
| FCF MarginFCF / Revenue | -45.8% | 83.0% |
| Capex IntensityCapex / Revenue | 55.2% | 0.1% |
| Cash ConversionOCF / Net Profit | 0.20× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $-103.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.4M | — | ||
| Q3 25 | $-7.6M | — | ||
| Q2 25 | $42.0M | — | ||
| Q1 25 | $-51.9M | $131.8M | ||
| Q4 24 | $55.1M | $-23.2M | ||
| Q3 24 | $-5.6M | — | ||
| Q2 24 | $36.7M | — | ||
| Q1 24 | $-5.6M | — |
| Q4 25 | $-55.2M | — | ||
| Q3 25 | $-18.0M | — | ||
| Q2 25 | $29.4M | — | ||
| Q1 25 | $-59.7M | $131.7M | ||
| Q4 24 | $-76.5M | $-23.2M | ||
| Q3 24 | $-27.7M | — | ||
| Q2 24 | $-500.0K | — | ||
| Q1 24 | $-57.1M | — |
| Q4 25 | -45.8% | — | ||
| Q3 25 | -15.5% | — | ||
| Q2 25 | 21.7% | — | ||
| Q1 25 | -46.5% | 83.0% | ||
| Q4 24 | -56.5% | -102.7% | ||
| Q3 24 | -21.7% | — | ||
| Q2 24 | -0.4% | — | ||
| Q1 24 | -41.9% | — |
| Q4 25 | 55.2% | — | ||
| Q3 25 | 8.9% | — | ||
| Q2 25 | 9.3% | — | ||
| Q1 25 | 6.1% | 0.1% | ||
| Q4 24 | 97.1% | 0.2% | ||
| Q3 24 | 17.3% | — | ||
| Q2 24 | 28.2% | — | ||
| Q1 24 | 37.8% | — |
| Q4 25 | 0.20× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 7.50× | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | 1.26× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KW
| Consolidated Portfolio Segment | $84.9M | 70% |
| Investment Management Fees | $30.4M | 25% |
| Real Estate | $5.1M | 4% |
STOK
Segment breakdown not available.
